The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Bisphosphonate Therapy Recommendations for Postmenopausal Osteoporosis

New Bisphosphonate Therapy Recommendations for Postmenopausal Osteoporosis

May 13, 2016 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
molekuul_be/shutterstock.com

molekuul_be/shutterstock.com

A task force of the American Society for Bone and Mineral Research (ASBMR) has released new recommendations delineating the potential benefits and risks of prolonged therapy with oral and IV bisphosphonate therapy and providing guidance on duration of bisphosphonate therapy for postmenopausal osteoporosis.1

You Might Also Like
  • Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Osteoporosis Screening Is Underutilized Despite Recommendations
Explore This Issue
May 2016
Also By This Author
  • Pain Linked to Inflammatory Lesions in Knee Osteoarthritis

The task force makes clear that data and clinical experience on which to base the recommendations are limited and that the approach for long-term bisphosphonate therapy use is based on evidence in mostly white postmenopausal women. Task force co-chairs Robert A. Adler, MD, and Ghada El-Hajj Fuleihan, MD, told The Rheumatologist, “Despite all the research in osteoporosis, our knowledge base for long-term management of this common chronic disorder is very limited.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Adler is chief of endocrinology and metabolism at McGuire Veterans Affairs Medical Center and professor of internal medicine at Virginia Commonwealth University School of Medicine in Richmond; Dr. El-Hajj Fuleihan is professor of medicine and founding director of the Calcium Metabolism and Osteoporosis Program at the American University of Beirut, Lebanon. The task force comprised experts in osteoporosis management, epidemiology, endocrinology, geriatrics and drug surveillance, a bone scientist not in the osteoporosis field and an ethicist.

Chief among the recommendations given in the report, Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research, is that a patient’s risk should be reassessed after five years of oral bisphosphonate therapy or three years of intravenous (IV) zoledronic acid therapy. Women at high risk, such as older women, those with a low hip T-score (less than or equal to -2.5) or high fracture risk score, those with a previous hip or spine fracture, or those who sustain a major osteoporotic fracture while on therapy, can be considered for treatment for up to 10 years of oral therapy or six years of IV therapy, with periodic evaluation, according to the recommendations.

Dr. Bolster

Dr. Bolster

“This recommendation reinforces the idea that the purpose of therapy is to reduce fracture, while also reflecting the lack of long-term fracture efficacy using these drugs and the long-term retention in bone,” Drs. Adler and El-Hajj Fuleihan told The Rheumatologist.

“Based on a benefit/risk ratio approach, the Task Force recommends treatment for the person at high risk for fracture at baseline and continued treatment for up to 10 years in those who are still at such risk three to five years after initiation of therapy. The tools to assess fracture risk are limited, and periodic assessment is based on clinical information, physical examination and DXA [dual-energy X-ray absorptiometry] measurements to stratify risks,” they say.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Guidelines Tagged With: Clinical, Osteoporosis, recommendations, therapy, TreatmentIssue: May 2016

You Might Also Like:
  • Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis
  • Novel Bone Drug Promising in Postmenopausal Osteoporosis
  • Osteoporosis Screening Is Underutilized Despite Recommendations
  • FDA Greenlights Osteoporosis Drug for Postmenopausal Women

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.